The anthracycline antibiotic doxorubicin produces a characteristic myopathy in cardiac muscle that limits its use in cancer therapy. We have shown in cultured neonatal rat cardiac muscle cells that doxorubicin treatment resulted in a rapid, selective decrease in the expression of muscle-specific genes, which preceded other changes characteristic of doxorubicin cardiomyopathy. Doxorubicin selectively and dramatically decreased the levels of mRNA for the sarcomeric genes, a-actin, troponin I, and myosin light chain 2, as well as the muscle-specific, but nonsarcomeric M isoform of creatine kinase. However, doxorubicin did not affect nonmuscle gene transcripts (pyruvate kinase, ferritin heavy chain, and 3-actin). Actinomycin D, an inhibitor of DNA-dependent RNA polymerase, did not show a similar selective decrease of muscle-specific mRNAs but, rather, produced a nonspecific, dose-dependent decrease of muscle and nonmuscle transcripts. The doxorubicin effect on muscle gene expression was limited to cardiac muscle; cultured skeletal myocytes were resistant to the effects of doxorubicin at 100-fold greater doses than those causing changes in mRNA levels in cardiac muscle cells. These effects of doxorubicin were reproduced in vivo; rats ih'ected with doxorubicin showed a dose-dependent decrease in the levels of mRNAs for a-actin, troponin I, myosin light chain 2, and M isoform of creatine kinase in cardiac but not skeletal muscle. These selective changes in gene expression in cardiocyte cultures and cardiac muscle precede classical ultrastructural changes and may explain the myofibrillar loss that characterizes doxorubicin cardiac injury.
sarcomeric genes, a-actin, troponin I, and myosin light chain 2, as well as the muscle-specific, but nonsarcomeric M isoform of creatine kinase. However, doxorubicin did not affect nonmuscle gene transcripts (pyruvate kinase, ferritin heavy chain, and 3-actin). Actinomycin D, an inhibitor of DNA-dependent RNA polymerase, did not show a similar selective decrease of muscle-specific mRNAs but, rather, produced a nonspecific, dose-dependent decrease of muscle and nonmuscle transcripts. The doxorubicin effect on muscle gene expression was limited to cardiac muscle; cultured skeletal myocytes were resistant to the effects of doxorubicin at 100-fold greater doses than those causing changes in mRNA levels in cardiac muscle cells. These effects of doxorubicin were reproduced in vivo; rats ih'ected with doxorubicin showed a dose-dependent decrease in the levels of mRNAs for a-actin, troponin I, myosin light chain 2, and M isoform of creatine kinase in cardiac but not skeletal muscle. These selective changes in gene expression in cardiocyte cultures and cardiac muscle precede classical ultrastructural changes and may explain the myofibrillar loss that characterizes doxorubicin cardiac injury. Doxorubicin is one of the most effective and widely used chemotherapeutic agents. It is used in the treatment of leukemias, lymphomas, and various solid tumors. However, this drug has cardiotoxic effects that restrict its full clinical potential. As cumulative drug doses exceed 500 mg/m2, the incidence of congestive heart failure increases rapidly, occurring in 15-30o of patients who have exceeded this dose. More than half of these patients die as a direct result of heart failure (1). Great effort has been directed at dissociating the beneficial effects of this drug from its cardiotoxicity by modifying the schedule of administration of doxorubicin and through evaluation of the ultrastructural changes in heart muscle (2, 3) . However, the mechanism underlying cardiotoxicity remains uncertain. Empiric attempts to limit cardiac toxicity have thus far only been partially successful [see review (4) ].
In myocardial tissue isolated by endomyocardial biopsy from humans treated with doxorubicin, the primary ultrastructural change is disruption and loss of myofibrils (5) . Alterations of the Z-band structure and disarray of the thin filaments are observed with doxorubicin treatment in vivo (6) and in vitro (7, 8) . The mechanism responsible for these changes is not understood. In this study we have addressed the hypothesis that the structural disintegration of myofibrils observed in doxorubicin treatment might be linked to alterations in the expression of genes coding for sarcomeric proteins.
MATERIALS AND METHODS
Cells and Cell Culture. Primary cultures of neonatal rat cardiac muscle cells were prepared by the method described by Simpson and Savion (9) and incubated for 48 hr before treatment with doxorubicin or actinomycin D. Differentiated human skeletal muscle cells were prepared from primary cultures of human skeletal myoblasts (10) as described (11) .
In certain experiments, 10 ,uM cytosine arabinonucleoside was added to remove replicating cells (11) . The rat skeletal muscle cell line L8 was cultured in Dulbecco's modified Eagle medium (DMEM) plus 20% fetal calf serum. Differentiation was initiated by replacing the medium with DMEM plus 2% horse serum; cells were maintained in this medium for 6 days before treatment with doxorubicin.
[3HJLeucine Incorporation. The doxorubicin effect on protein synthesis in cultured cardiac cells was evaluated by trichloroacetic acid precipitation following incubation with 1 tkCi of [3H]leucine (1 Ci = 37 GBq) for 4 hr.
Sample Preparation for Electron Microscopy. Cultured cardiac muscle cells and rat heart tissue were fixed for 2 hr in 1% glutaraldehyde in 0.067 M sodium cacodylate (pH 7.4), washed in buffer, and postfixed in 2% osmium tetroxide for 1 hr. The samples were prestained in 1% uranyl acetate, dehydrated in a graded ethanol series, and embedded in 100% epoxy resin. After sectioning, samples were mounted on parlodian-coated grids, stained with lead citrate, and examined with a Philips 201C electron microscope.
Immunofluorescence Staining and Cell Count. Cardiac muscle cells were distinguished from nonmuscle cells by immunofluorescence staining of myosin heavy chain (MHC) as described by Silberstein et al. (12) . The monoclonal antibody for myosin heavy chain (4A.1025) was a gift of H. Blau (Stanford, CA). Phase-contrast and fluorescence fields were Abbreviations: MLC, myosin light chain; PK, pyruvate kinase; FH, ferritin heavy chain; M-CK, M isoform of creatine kinase; MHC, myosin heavy chain.
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Isolation and Analysis of RNA. RNA was isolated from cells or tissue by lysis in guanidine thiocyanate and centrifugation through a 5.7 M CsCl cushion (13) . RNA was analyzed by Northern or dot blotting followed by hybridization to [32P] cDNA probes prepared by the random primer method (14) as described (11, 15) .
cDNA Probes. The following cDNAs were used in this study: human cardiac a-actin (16), human 18-actin (17) , rat cardiac troponin I (R.W. and R.G., unpublished data), human myosin light chain 2 (MLC 2) slow (G.L. and R.W., unpublished data), rat pyruvate kinase (PK) (18) , mouse ferritin heavy chain (FH) (15) , and human M isoform of creatine kinase (M-CK) (19) .
In Vivo Experiments. Male Sprague-Dawley rats (150-200 g) were anesthetized by intraperitoneal injection of 10 mg of xylazine per kg and 50 mg of ketamine hydrochloride per kg and injected intravenously with varying doses of doxorubicin (dissolved in normal saline). Control rats received an injection of normal saline. Twenty-four hours after the injection rats were sacrificed by asphyxiation. For the dose-response experiments, RNAs from five rat hearts per each dose group (2, 20 , and 40 mg/kg) and six controls were evaluated by dot blots. In separate experiments designed to compare gene expression in cardiac and skeletal muscle, femoral muscle and heart were removed from the same animals (three control rats and four rats treated with doxorubicin at 20 mg/kg). The RNA was analyzed by Northern blots. Hearts obtained from control and doxorubicin-treated (20 and was undetectable at 0.5 ,uM. Further, these decreases in muscle-specific mRNAs with 0.2 ,uM doxorubicin were observed after only 8 hr, a time point preceding any effect on total protein synthesis. For example, at 8 hr 0.2 ,uM doxorubicin caused a 49%, 62%, and 54% reduction of a-actin, MLC 2, and troponin I transcripts, respectively.
To determine whether the effect ofdoxorubicin was limited to sarcomeric genes, we examined whether doxorubicin treatment would lead to a decrease in the mRNA for a nonsarcomeric, but muscle-specific protein, such as the M-CK (19, 20) . Treatment of cultured cardiac muscle cells for 24 hr with 0.5 ,uM doxorubicin led to a marked reduction of the muscle-specific M-CK mRNA (Fig. 2 Right) . Do Nonmuscle Cells Contribute to the Doxorubicin Effect on Gene Expression? Our cardiac cultures contain 410% cells negative for MHC by immunofluorescence ("nonmuscle cells"). To examine whether the apparent selective effect of doxorubicin on muscle gene expression merely reflected the relative resistance of these nonmuscle cells to doxorubicin (that nonmuscle cells made a disproportionate contribution to the total mRNA for 8-actin, FH, and PK), we further reduced the proportion of nonmuscle cells with cytosine arabinonucleoside treatment. After 48 hr of pretreatment with 10 ,uM cytosine arabinonucleoside, cells were treated with and without 0.5 ,uM doxorubicin for 24 hr in the presence of cytosine arabinonucleoside. At the end of the cytosine arabinonucleoside treatment, the percentage of MHC stained cells as determined by immunofluorescence microscopy was 98%, as compared to 89% in the absence of cytosine arabinonucleoside. The effect of doxorubicin on 6-actin, FH, and PK transcripts was identical in cytosine arabinonucleosidetreated cells and control cells (data not shown), demonstrating that nonmuscle cells did not contribute to the selective decrease in muscle-specific transcripts observed with doxorubicin.
Actinomycin D Effect on Gene Expression in Cardiac Cells. We also considered the possibility that the selectivity of doxorubicin on muscle-specific mRNAs might in fact result from a nonspecific inhibition of gene expression-that this apparently selective effect might be a consequence of shorter half-lives for muscle-specific transcripts. To test this possibility, we used actinomycin D, an inhibitor of DNAdependent RNA polymerase. Actinomycin D did not show a selective inhibition of muscle-specific transcripts similar to doxorubicin but, rather, produced a nonspecific, dosedependent inhibition of muscle and nonmuscle mRNAs (Fig. 3) . Doxorubicin Effect on Gene Expression in Skeletal Muscle Cells. Generally, it is thought that skeletal muscle is more resistant to doxorubicin toxicity than cardiac muscle. Is the selective decrease in muscle-specific gene expression by doxorubicin limited to cardiac cells? To approach this question, we performed Northern blot analysis with RNA isolated from doxorubicin-treated cultures of primary human skeletal muscle and rat myocytes. Cultured skeletal myotubes (see Materials and Methods) were resistant to any effect of doxorubicin on the mRNAs examined. Even 50 ,uM doxorubicin treatment for 24 hr (100 times the concentration at which changes in gene expression were observed in cardiac muscle cells) caused no decrease of either muscle-specific (a-actin, M-CK) or nonmuscle (PK) transcripts in skeletal muscle cells (Fig. 4 ). An experiment of identical design was performed using rat skeletal muscle L8 cells. Differentiated L8 cells were also resistant up to 50 ,4M doxorubicin treatment (data not shown).
Doxorubicin Effect on Gene Expression and Ultrastructure in Adult Rat Hearts. To determine whether doxorubicin effects on muscle-specific mRNA were limited to cardiac muscle cells in tissue culture, we performed an in vivo study using adult rats. Total RNA was isolated from the hearts of control rats and rats treated with doxorubicin (doses of 2, 20, and 40 mg/kg) for 24 hr. Dot blots were probed with a-actin, troponin I, MLC 2, and M-CK cDNA. Autoradiograms were analyzed by densitometry, and the results were normalized for PK expression. A dose-dependent reduction in musclespecific mRNA was observed (Fig. 5) .
To compare the doxorubicin effect on cardiac and skeletal muscle in vivo, cardiac and skeletal mRNAs from three control and four doxorubicin-treated rats were analyzed by Northern blots. Neither a-actin (Fig. 6) despite the inhibition of a-actin and M-CK gene expression in cardiac muscle isolated from the same rats.
Tissue samples from hearts of control and doxorubicintreated animals (20 mg/kg) from these experiments were prepared for electron microscopy and examined for evidence of cardiotoxicity. In contrast to the marked effect on mRNA levels observed after 24 hr, no remarkable ultrastructural changes were observed up to 3 days after the injection of 20 mg of doxorubicin per kg. However, 8 days after the treatment, most of the myocardium showed myofibrillar loss and sarcotubular swelling as well as other evidence of cell injury, such as mitochondrial damage (Fig. 7) .
DISCUSSION
Although the last 15 years have witnessed considerable effort toward clarifying the mechanism of doxorubicin cardiotoxicity, the sequence of events leading to myocardial damage has remained elusive. One widely held hypothesis associates doxorubicin cardiotoxicity with the generation ofoxygen free radicals that disrupt DNA, membrane proteins, and phos- 5 . Expression of muscle-specific genes in doxorubicintreated hearts from adult rats. Total RNA from hearts isolated from rats treated with various doses of doxorubicin was applied to nitrocellulose in a dot blot apparatus. The autoradiograms were analyzed by densitometry and the results are expressed as the ratio of a-actin, troponin I, MLC 2, or M-CK normalized to PK. Data are shown as the mean SEM of five rats per each dose group and six rats in the control group. Significant differences from the control level of expression were observed for all muscle-specific gene expression at 20 mg/kg and 40 mg/kg (P < 0.01).
Proc. Natl. Acad. Sci. USA 87 (1990) pholipids (21) (22) (23) . Other hypotheses with strong experimental support have also been proposed, including a role for a metabolite of doxorubicin (24) in the etiology of cardiotoxicity. Several studies have suggested the interaction of doxorubicin with myofibrillar proteins in the etiology of doxorubicin cardiotoxicity (25, 26 (27) , and that model early stages of doxorubicin cardiotoxicity, were chosen. With these concentrations, the steadystate levels of the mRNAs of three sarcomeric muscle genes, a-actin, MLC 2 (slow), and cardiac troponin I, and one muscle-specific, but nonsarcomeric gene, the M-CK, were all markedly decreased by doxorubicin treatment (Fig. 2) . In contrast, the transcripts of three nonmuscle genes were unaffected. Nonmuscle mRNAs were chosen from genes involved in different cellular functions: f3-actin, in.cytoskeletal structure; FH, in iron storage; and PK, in glycolysis. (Fig. 7) . The resistance of skeletal muscle to doxorubicin was also shown in vivo: mRNAs from muscle genes were evaluated in skeletal and cardiac tissues from the same rats treated with doxorubicin. In all animals tested, the selective decrease in muscle genes was observed only in cardiac muscle (Fig. 6 ).
This report demonstrates that the cardiomyopathy produced by doxorubicin is associated with alterations in the expression of genes important for the structural integrity and enzymatic functions of cardiac muscle. Although no experimental system can be expected to model every aspect of the complex interaction between patient, disease, and drug, the fidelity of these in vitro results to in vivo changes suggests that selective inhibition of muscle gene expression may be an early event leading to the largely irreversible and sometimes fatal cardiomyopathy in patients treated with doxorubicin.
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